[Twenty-five years of cyclosporin use in transplantation medicine].
Cyclosporin has greatly improved the short and medium-term outcomes for solid organ transplantation. However, the effect on the long-term outcome has been less impressive. This can partly be attributed to the side effects of cyclosporin, and partly to the fact that the use of cyclosporin has not led to a reduced incidence of chronic allograft nephropathy. Efforts to minimise these side effects have led to the development of the microemulsion form of cyclosporin and improved methods for therapeutic drug monitoring (dosage based on blood levels instead of body weight). Finally, the introduction of new immunosuppressive drugs has made it possible to further reduce the dose of cyclosporin; this might eventually lead to cyclosporin-free immunosuppressive regimens.
Hesselink
D A
DA
Afd. Inwendige Geneeskunde, sectie Transplantatie, Erasmus Medisch Centrum, Dr. Molewaterplein 50, 3015 GE Rotterdam. hesselink@erasmusmc.nl
van Hagen
P M
PM
Balk
A H M M
AH
van Hal
P Th W
PT
Weimar
W
W
van Gelder
T
T
D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004339:Drug Compounding; D004655:Emulsions; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016377:Organ Transplantation; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D004655:Emulsions; D007166:Immunosuppressive Agents; D016572:Cyclosporine